Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 60Lymphoma 56Leukemia, Myeloid, Acute 51Leukemia 50Lymphoma, Non-Hodgkin 48Precursor Cell Lymphoblastic Leukemia-Lymphoma 46Hodgkin Disease 36Myelodysplastic Syndromes 28Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 24Lymphoma, Mantle-Cell 23Neuroblastoma 22Leukemia, Lymphocytic, Chronic, B-Cell 22Burkitt Lymphoma 17Lymphoma, Follicular 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Central Nervous System Neoplasms 13Lymphoma, Large-Cell, Immunoblastic 12Sarcoma 11Neoplasms, Plasma Cell 11Brain Neoplasms 11Recurrence 10Lymphoma, B-Cell, Marginal Zone 10Neoplasms 9Hematologic Neoplasms 9Congenital Abnormalities 9Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Leukemia, Biphenotypic, Acute 8Graft vs Host Disease 8

Interventions

Bortezomib 5Dexamethasone 4Lenalidomide 3Granulocyte Colony-Stimulating Factor 3fludarabine 2filanesib 2dacetuzumab 2Steroids 2Injections, Subcutaneous 2Filgrastim 2plerixafor 1ofatumumab 1isatuximab 1fludarabine phosphate 1ficlatuzumab 1birtamimab 1Zoledronic Acid 1Whole-Body Irradiation 1Vorinostat 1Tacrolimus 1Rifaximin 1Proteasome Inhibitors 1Plasma Exchange 1Mycophenolic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Denosumab 1Cyclophosphamide 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Paraproteinemias × Granulocyte Colony-Stimulating Factor × Clear all
NCT01186224 2025-03-17

PHANTASTIC

University of Liverpool

Phase NA Completed
60 enrolled
LymphoidPlasma cell

Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias

NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡